Sanofi India Ltd has recalled its four batches of famous painkiller combination, after the Indian regulator found the product to be sub-standard.

water_medicine_hires

“There is a pharmaceutical parameter that requires the breakdown of a tablet in the human body to be assessed. In the case of Combiflam, though the disintegration time was delayed, doctors and patients can be assured that there is no impact on the safety and efficacy of the product,” Sanofi said.

Combiflam, is a combination of paracetamol and ibuprofen, it is the second largest brand in the non-steroidal anti-inflammatory (NSAID) market, with sales of Rs.162.7 crore, for the last financial year.

The Drugs Controller General of India (DCGI) was already issued safety alert first in February and then again in April, after some batches of Combiflam were found not of standard quality due to delayed disintegration of the molecule in the blood stream.

The tablets were manufactured at Sanofi’s factory in Ankleshwar, Gujarat.

Also Read :  The 10 Antique Medical Photos That Will Take You To The Unseen History!

On the flip side, shares of Sanofi dropped 0.67% to Rs.4318.50 on BSE while the benchmark Sensex declined 0.68% to 25,597.02 points.

Now You Can Get the Latest Buzz On Your Phone! Download the PagalParrot Mobile App For Android and IOS